California Prisons Lead Nation in Naloxone Access, Allow Inmates to Carry Life-Saving Medication

California's prison system has documented more than 7,000 overdose reversals since 2019, a figure that understates the scale of a quiet revolution unfolding inside the state's correctional facilities. Between 2019 and 2024, staff and incarcerated individuals administered naloxone thousands of times, transforming what would have been fatal overdoses into survival stories that rarely make headlines but collectively represent one of the most ambitious harm reduction programs in American corrections.

The California Department of Corrections and Rehabilitation (CDCR) announced this week that it has completed statewide installation of self-service naloxone dispensers, distributing 286,061 kits during fiscal year 2024–25 alone. But the scale of the distribution program tells only part of the story. What distinguishes California from every other state prison system in the nation is a policy shift that once seemed unthinkable: incarcerated individuals are now allowed to carry naloxone inside prison walls.

Breaking the Access Barrier

CDCR is the only U.S. state prison system that permits people in custody to possess naloxone, a policy Barbara Barney-Knox, Deputy Director of Nursing Services, describes as essential to rapid overdose response. "As nursing staff, we know how access to naloxone saves lives and preserves opportunity for life-changing treatment," she said in a statement released Monday. "CDCR is leading the way among state correctional systems by making sure this medication is readily available to staff and incarcerated individuals when it matters most."

The decision to allow peer-to-peer naloxone administration inside facilities represents a fundamental departure from traditional correctional approaches that prioritize control over harm reduction. In most prison systems, an overdose requires finding a staff member, unlocking doors, navigating institutional protocols—a process measured in minutes that often determines whether someone lives or dies. California's model compresses that timeline by placing naloxone directly in the hands of people who are most likely to witness an overdose first.

Since 2020, CDCR has distributed more than 114,000 naloxone kits at release, with over 95 percent of individuals leaving custody receiving overdose education and a take-home kit. The distribution rate approaches universal coverage, a threshold few community-based harm reduction programs achieve. But the impact extends beyond the moment of release. National data cited by CDCR shows that medication-assisted treatment (MAT) reduces all-cause mortality by up to 85 percent and overdose death risk by approximately 75 percent after release—figures that underscore how naloxone distribution functions as a bridge connecting people from overdose crisis to sustained treatment engagement.

Training Staff, Saving Lives

The expansion of naloxone access required a cultural shift inside institutions where many staff members had never administered the medication. Naloxone administrations by healthcare staff have increased 2,000 percent since the program's implementation, while custody staff—correctional officers who work directly with incarcerated populations—have seen a 4,147 percent increase in naloxone use.

The disparity in those percentages reflects both the starting point (custody staff rarely carried naloxone before 2020) and the reality that overdoses don't occur on a predictable schedule or in locations where healthcare workers are immediately available. Custody staff are often first on scene, and their willingness to administer naloxone has become critical to the program's success.

The statewide installation of self-service naloxone dispensers—completed by March 2025—represents the latest phase in CDCR's harm reduction strategy. Unlike traditional medical dispensing that requires navigating bureaucracy or waiting for scheduled appointments, self-service dispensers allow immediate access. The 286,061 kits distributed through these machines in fiscal year 2024–25 suggest demand far exceeds what staff-only distribution could have achieved.

Overdose Risk Behind Bars and Beyond

Justice-involved populations face overdose risk at rates that dwarf those of the general public, a disparity driven by forced abstinence during incarceration, loss of opioid tolerance, and the unpredictable potency of illicit drugs. The first two weeks after release represent a particularly dangerous window: people who maintained sobriety in custody often return to communities where fentanyl-contaminated drugs have become the norm, and their diminished tolerance makes what was once a survivable dose potentially fatal.

CDCR's naloxone program addresses both in-custody overdoses and post-release risk. By ensuring that nearly everyone leaving California prisons carries naloxone and knows how to use it, the state is attempting to extend the protective reach of harm reduction beyond the prison gate. But the policy of allowing incarcerated individuals to carry naloxone inside facilities addresses a different problem: overdoses are happening in custody, and the systems designed to prevent drug use haven't eliminated it.

California's decision to acknowledge that reality rather than double down on enforcement-only approaches reflects a pragmatic recognition that people will use drugs in prison regardless of rules, and that preventing deaths requires meeting people where they are rather than where policy assumes they should be.

A National Model—or an Outlier?

CDCR operates what Barbara Barney-Knox describes as "one of the largest naloxone education and distribution programs in the nation," a claim supported by the numbers: 7,000-plus overdose reversals documented over five years, with thousands more expected when 2025 data becomes available. No other state prison system has publicly reported figures approaching that scale.

The question now is whether other states will follow California's lead. Most correctional systems remain locked in older paradigms where providing naloxone to incarcerated individuals would be seen as condoning drug use rather than acknowledging the failure of prohibition to eliminate it. But as synthetic opioids drive overdose deaths higher—even inside prisons where access to drugs is theoretically controlled—the case for harm reduction becomes harder to ignore.

"Prioritizing naloxone distribution has allowed us to respond quickly to overdoses and prevent countless deaths," Barney-Knox said. "CDCR will continue to focus on evidence-based harm reduction strategies (and) expand access to care. (We will) do everything we can to reduce opioid overdoses and overdose deaths."

By integrating naloxone access with the Integrated Substance Use Disorder Treatment (ISUDT) Program's MAT offerings, CDCR has built infrastructure that extends from overdose reversal to long-term recovery support. The model is scalable, evidence-based, and—given the overdose reversal numbers—demonstrably effective at keeping people alive long enough to access treatment.

Whether other states replicate California's approach will depend less on evidence (which is clear) than on politics, institutional culture, and the willingness of correctional leaders to prioritize public health over symbolic gestures toward a drug-free prison that has never existed. For now, California remains the exception, a system that decided saving lives matters more than maintaining the illusion of control. The 7,000 people who survived overdoses because naloxone was available when it mattered most suggest the choice was the right one.